Taurochenodeoxycholic acid
Based on 9 publication(s) in Google Scholar
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 516-35-8
- Formula: C26H45NO6S
- Molecular Weight:499.70
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Human Endogenous Metabolite Compound Library
HY-L030
-
Drug Repurposing Compound Library
HY-L035
-
Lipid Compound Library
HY-L043
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Pyroptosis Compound Library
HY-L059
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Gut Microbial Metabolite Library
HY-L078
-
Microbial Metabolite Library
HY-L084
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Food-Sourced Compound Library
HY-L094
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Animal-Sourced Natural Product Library
HY-L157
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Endogenous Metabolite Library
HY-L207
-
Bile Acids Library
HY-L208
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Mouse Metabolite Compound Library
HY-L217
-
Lipid Metabolite Compound Library
HY-L228
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Taurochenodeoxycholic acid
More- Nature. 2025 Jul;643(8070):192-200. [Abstract]
- Nat Microbiol. 2023 Jan;8(1):91-106. [Abstract]
- Adv Sci (Weinh). 2025 Feb 3:e2411719. [Abstract]
- J Transl Med. 2024 Dec 20;22(1):1124. [Abstract]
- Cancer Cell Int. 2025 Apr 22;25(1):160. [Abstract]
- Food Funct. 2026 Jun 22. [Abstract]
- Biomedicines. 2025 Apr 4;13(4):874. [Abstract]
- J Pharm Biomed Anal. 2025 Jul 15:259:116760. [Abstract]
- SSRN. 2022 Jan 26.
Customer Validation & Images
-
RT-PCR
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
-
Histological Imaging/Staining
All Caspase Isoforms
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Microbial Metabolite |
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
1.92 μM
Compound: 4a, tauro
|
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
|
[PMID: 18307294] |
| HEK293 | EC50 |
2.3 μM
Compound: TCDC
|
Agonist activity at wild type human TGR5 expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay
Agonist activity at wild type human TGR5 expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay
|
[PMID: 26435512] |
| HEK293 | EC50 |
29.57 μM
Compound: TCDC
|
Agonist activity at human TGR5 Y89A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay
Agonist activity at human TGR5 Y89A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay
|
[PMID: 26435512] |
| HEK293 | IC50 |
55 μM
Compound: Taurochenodeoxycholate
|
TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing HEK-293 cells
TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing HEK-293 cells
|
[PMID: 12523936] |
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, Taurochenodeoxycholic acid significantly augments PKC mRNA levels, activities and increases JNK, caspase-3 and caspase-8 mRNA expression levels, activities[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation[3].
Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 516-35-8
-
Appearance Solid
-
Molecular Weight 499.70
-
Formula C26H45NO6S
-
Color White to off-white
-
SMILES
C[C@@]1([C@@]2([H])[C@H](C)CCC(NCCS(=O)(O)=O)=O)[C@](CC2)([H])[C@@]([C@@H](C[C@]3([H])C[C@H](O)CC4)O)([H])[C@]([C@]34C)([H])CC1
-
Synonyms
12-Deoxycholyltaurine
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Jul;643(8070):192-200. PMID: 39695227 -
Nat Microbiol
2023 Jan;8(1):91-106. PMID: 36604506 -
Adv Sci (Weinh)
Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]2025 Feb 3:e2411719. PMID: 39899681
Taurochenodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb 3:e2411719. [Abstract]
The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.
-
J Transl Med
Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation. [Abstract]2024 Dec 20;22(1):1124. PMID: 39707318
Taurochenodeoxycholic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Dec 20;22(1):1124. [Abstract]
Univariate analysis of major serum bile acids in WT d and e mice of control and SAP model. (3 mM TCDCA).
Taurochenodeoxycholic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Dec 20;22(1):1124. [Abstract]
A notable reduction in serum amylase and lipase levels was observed following TCDCA supplementation.
Taurochenodeoxycholic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Dec 20;22(1):1124. [Abstract]
TCDCA alleviates pancreatitis via TGR5 and NLRP3 signaling. 3 mM TCDCA was added to the drinking water for 4 weeks before caerulein injection SAP models. Samples were at 12 h post caerulein-induced SAP modeling (n=6).
-
Cancer Cell Int
Taurochenodeoxycholic acid suppresses the progression of glioblastoma via HMGCS1/HMGCR/GPX4 signaling pathway in vitro and in vivo. [Abstract]2025 Apr 22;25(1):160. PMID: 40264142 -
Food Funct
Association between daidzein metabolism to equol and fecal bile acid profiles in young women. [Abstract]2026 Jun 22. PMID: 42329218 -
Biomedicines
2025 Apr 4;13(4):874. PMID: 40299495 -
J Pharm Biomed Anal
Integrating 16S rDNA sequencing analysis and targeted metabolomics to explore the mechanism of Xiexin Tang in treating atherosclerosis mice induced by high-fat diet. [Abstract]2025 Jul 15:259:116760. PMID: 40014894 -
Solvent & Solubility
Methanol : ≥ 100 mg/mL (200.12 mM)
H2O : 100 mg/mL (200.12 mM; Need ultrasonic)
DMSO : ≥ 25 mg/mL (50.03 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (200.12 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
Rats: Male Wistar rats are divided into six groups of ten each. Group 1 is normal rat (Sham), Group 2 received FCA only, Group 3 and Group 4 received FCA+Taurochenodeoxycholic acid (0.1 g/kg) and FCA+Taurochenodeoxycholic acid (0.2 g/kg), respectively, Groups 3 and 4 are treated beginning from day 0 of injection of FCA, Group 5 and Group 6 received FCA+Taurochenodeoxycholic acid (0.1 g/kg) and FCA+Taurochenodeoxycholic acid (0.2 g/kg), respectively, Group 5 and Group 6 are treated from 14 days after induction. All animals are treated with intragastrical administration and sacrificed after 28 days of induction[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (647 KB)
- English - EN (647 KB)
- Français - FR (647 KB)
- Deutsch - DE (647 KB)
- Norwegian - NO (647 KB)
- Español - ES (647 KB)
- Swedish - SV (647 KB)
- Italian - IT (647 KB)
- Portuguese - PT (647 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway. Eur J Pharmacol. 2016 Sep 5;786:109-15. [Content Brief]
[2]. Zhou C, et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak J Pharm Sci. 2013 Jul;26(4):761-5. [Content Brief]
[3]. Uchida A, et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol. 1997 May;272(5 Pt 1):G1249-57. [Content Brief]
[4]. Liu M, et al. Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. Int Immunopharmacol. 2011 Dec;11(12):2150-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Methanol / H2O | 1 mM | 2.0012 mL | 10.0060 mL | 20.0120 mL | 50.0300 mL |
| 5 mM | 0.4002 mL | 2.0012 mL | 4.0024 mL | 10.0060 mL | |
| 10 mM | 0.2001 mL | 1.0006 mL | 2.0012 mL | 5.0030 mL | |
| 15 mM | 0.1334 mL | 0.6671 mL | 1.3341 mL | 3.3353 mL | |
| 20 mM | 0.1001 mL | 0.5003 mL | 1.0006 mL | 2.5015 mL | |
| 25 mM | 0.0800 mL | 0.4002 mL | 0.8005 mL | 2.0012 mL | |
| 30 mM | 0.0667 mL | 0.3335 mL | 0.6671 mL | 1.6677 mL | |
| 40 mM | 0.0500 mL | 0.2502 mL | 0.5003 mL | 1.2508 mL | |
| 50 mM | 0.0400 mL | 0.2001 mL | 0.4002 mL | 1.0006 mL | |
| Methanol / H2O | 60 mM | 0.0334 mL | 0.1668 mL | 0.3335 mL | 0.8338 mL |
| 80 mM | 0.0250 mL | 0.1251 mL | 0.2502 mL | 0.6254 mL | |
| 100 mM | 0.0200 mL | 0.1001 mL | 0.2001 mL | 0.5003 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz